Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

513.12
-7.8800-1.51%
Post-market: 513.310.1900+0.04%19:30 EDT
Volume:415.57K
Turnover:215.18M
Market Cap:22.01B
PE:18.36
High:528.02
Open:523.23
Low:512.29
Close:521.00
52wk High:609.35
52wk Low:302.19
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.96
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.44
PE(LYR):18.42

Loading ...

United Therapeutics CEO Martine Rothblatt disposes 9,500 shares worth $5.5 million

Reuters
·
Apr 24

United Therapeutics CEO Martine Rothblatt disposes of shares worth $5.3 million

Reuters
·
Apr 23

Press Release: United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

Dow Jones
·
Apr 22

United Therapeutics to report first-quarter results, host webcast before market open

Reuters
·
Apr 22

United Therapeutics CFO James Edgemond disposes of shares worth $5,715,739.33

Reuters
·
Apr 21

United Therapeutics CEO Martine Rothblatt disposes of shares worth $4,902,773

Reuters
·
Apr 21

United Therapeutics says ARTISAN interim data show early high-dose treprostinil improves PAH heart function

Reuters
·
Apr 20

United Therapeutics director Christopher Patusky sells USD 578,880 common shares

Reuters
·
Apr 18

United Therapeutics CEO Martine Rothblatt disposes 9,500 shares for $5.49 million

Reuters
·
Apr 18

United Therapeutics CFO James Edgemond disposes of shares worth $5.2 million

Reuters
·
Apr 18

Top Executive Makes Notable Move With United Therapeutics Shares

TIPRANKS
·
Apr 17

United Therapeutics CEO Martine Rothblatt disposes of shares worth $10.97 million

Reuters
·
Apr 17

United Therapeutics EVP, General Counsel Paul Mahon sells 8,300 shares for $4.8 million

Reuters
·
Apr 17

How FDA RMAT Status For Bioengineered Liver Device At United Therapeutics (UTHR) Has Changed Its Investment Story

Simply Wall St.
·
Apr 16

United Therapeutics CEO Martine Rothblatt disposes of USD 5.7 million common shares

Reuters
·
Apr 15

United Therapeutics CFO James Edgemond disposes of common shares worth $5,747,755.31

Reuters
·
Apr 15

United Therapeutics CEO Martine Rothblatt disposes common shares worth $5,378,572.62

Reuters
·
Apr 14

A Look At United Therapeutics (UTHR) Valuation After RMAT Win And Tyvaso Phase 3 Success

Simply Wall St.
·
Apr 12

United Therapeutics CFO James Edgemond disposes of USD 5.2 million common shares

Reuters
·
Apr 11

United Therapeutics CEO Martine Rothblatt disposes of shares worth $5.45 million

Reuters
·
Apr 11